Full Length ArticleThe impact of new-onset cancer among veterans who are receiving warfarin for atrial fibrillation and venous thromboembolism☆
Section snippets
Background
Warfarin therapy remains a mainstay of treatment for both atrial fibrillation (AF) and venous thromboembolism (VTE) for thousands of Americans as a means to reduce incidence of embolic stroke and recurrent VTE, respectively [1]. However, a new cancer diagnosis adds complexity and uncertainty to the management of anticoagulation for these patients. Previous work by our group has shown that patients who receive warfarin for any reason who are diagnosed with cancer will have worse anticoagulation
Patient sample
All procedures were approved by the Bedford Veterans' Administration (VA) Institutional Review Board. This was a retrospective cohort study. We obtained encounter, demographic, laboratory and pharmacy fill data from the VA Clinical Data Warehouse and Medicare for 122,875 veterans who had ever received warfarin in a VA anticoagulation clinic from October 1, 2006 through September 30, 2008 (Fig. 1). Patients were deemed to have been receiving warfarin 1) while they were in possession of warfarin,
Anticoagulation control by indication for therapy
From the original 122,875 patients in our sample, 47,071 patients met inclusion criteria for warfarin use during the study period. After excluding 181 patients who were receiving warfarin for an indication other than AF or VTE, we had a sample of 46,890 patients who constituted our base analytic sample (Fig. 1). This sample of patients was 98.5% male, all over the age of 65, and 89.6% white race. Demographic profiles of patients with incident cancer were similar for each indication, except for
Discussion
In this sample of veterans who were receiving chronic warfarin therapy for either AF or VTE and were diagnosed with new-onset cancer, we have shown that the new cancer diagnosis significantly worsens warfarin control in the six-month period following diagnosis compared to the cancer-free cohort, regardless of indication for anticoagulation. This finding is especially pertinent when considering the lack of available clinical guidelines in the management of AF following cancer diagnosis [6], as
Conclusion
Among patients receiving warfarin who develop a new-onset cancer diagnosis, patients experience poorer anticoagulation control during the first six months after a new cancer diagnosis, a phenomenon which is similar between patients anticoagulated for AF or VTE, and which does not persist when examined 7–12 months after cancer onset. Given that patients anticoagulated for AF are more than 2.5 times as numerous as patients anticoagulated for VTE, future research should specifically address whether
Authorship addendum
D.B. Ambrus, MD, MSc: Primary role in conceptualization of the research question, guidance of data analysis and drafting of the manuscript.
J.I. Reisman, BA: Primary role in obtaining the data set, primary role in performing and guiding data analysis, and critical writing/revision of intellectual content.
A.J. Rose, MD, MSc: Role in conceptualization of the research question, design and guidance of data analysis, and critical writing/revision of intellectual content, obtaining funding, and study
References (18)
- et al.
Patient characteristics associated with oral anticoagulation control: results of the Veterans AffaiRs Study to Improve Anticoagulation (VARIA)
J. Thromb. Haemost.
(2010) - et al.
Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines
Chest
(2012) - et al.
2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society
J. Am. Coll. Cardiol.
(2011) - et al.
Identifying major hemorrhage with automated data: results of the Veterans Affairs Study to Improve Anticoagulation (VARIA)
Thromb. Res.
(2013) - et al.
Determinants of oral anticoagulation control in new warfarin patients: analysis using data from clinical practice research datalink
Thromb. Res.
(2015) - et al.
National trends in oral anticoagulant use in the United States, 2007 to 2011
Circ. Cardiovasc. Qual. Outcomes
(2012) - et al.
Effectiveness of warfarin among patients with cancer
J. Gen. Intern. Med.
(2007) - et al.
American College of Chest P. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines
Chest
(2012) - et al.
Stratifying the risks of oral anticoagulation in patients with liver disease
Circ. Cardiovasc. Qual. Outcomes
(2014)
Cited by (18)
Optimizing antithrombotic therapy for atrial fibrillation in cancer
2022, Thrombosis ResearchStroke risk assessment and atrial fibrillation (AF) in cancer patients
2022, Cardiovascular Toxicity and Therapeutic Modalities Targeting Cardio-oncology: From Basic Research to Advanced StudyAssociation of anticoagulant-related bleeding events with cancer detection in atrial fibrillation: A systematic review and meta-analysis
2021, Hellenic Journal of CardiologyCitation Excerpt :Michaels in 1962 was the first who noted the above association by presenting 3 case reports.22 The reported incidence of cancer in cohorts of patients under an NOAC or a VKA ranged between 1.2%-4.6%19,21 and 0.5%-5.7%,15,23 respectively. Warfarin is less often associated with GI bleeding than NOACs,24 because of the incomplete absorption of the NOACs as compared to warfarin across the GI mucosa and thus the potential for topical drug activity.25
Atrial fibrillation and cancer – An unexplored field in cardiovascular oncology
2019, Blood ReviewsCitation Excerpt :Due to the possibility of drug-drug interaction between anticoagulant treatment and various chemotherapies, certain vigilance is required as inadequate dosing and suboptimal therapy could result in an increased risk for thromboembolic and bleeding complications. In a cohort study with 122,875 veterans, it was shown that patients under warfarin therapy, who were newly diagnosed with cancer, experience a significant decrease in time in therapeutic range (TTR) in the first 6 months after diagnosis [75]. In a nested-case control study in a primary health care database, cancer was found as one of the strongest predictors of supra-therapeutic anticoagulation (INR ≥ 4) [76].
Atrial fibrillation in patients with active malignancy and use of anticoagulants: Under-prescription but no adverse impact on all-cause mortality
2019, European Journal of Internal MedicineCitation Excerpt :This finding was observed in the whole population, as well as in analysis of subgroups. Our results are of clinical interest, even with the limitations of their observational nature, since according to published literature, patients with cancer taking warfarin have an increased risk (up to twofold) of major and fatal bleeding, as compared to non-cancer patients taking warfarin [40]. Therefore a potential impact of anticoagulation on the risk of bleeding and death is often assumed.
Anticoagulant Agents for Atrial Fibrillation in Cancer Patients
2018, American Journal of Cardiology
- ☆
This study was supported by funding from the Veterans' Affairs Health Services Research and Development grant IIR-10-374. This article does not necessarily represent the official views or policies of the United States Department of Veterans Affairs.